Cystic fibrosis has become the poster child for precision medicine – most new therapies are carefully tailored to a CF patient’s genetic makeup. University of North Carolina spinout Spyryx Biosciences is proposing a one-size-fits-all approach to the disease: It’s developing a peptide-based therapy that, in theory, could be effective among all CF patients.
This startup’s in the earliest of stages – it’s still pre-IND, and only beginning to emerge from stealth mode. The underlying research comes from University of North Carolina School of Medicine researcher Robert Tarran.
Help employers find you! Check out all the jobs and post your resume.
